[go: up one dir, main page]

JPH09501936A - 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 - Google Patents

生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置

Info

Publication number
JPH09501936A
JPH09501936A JP7507766A JP50776695A JPH09501936A JP H09501936 A JPH09501936 A JP H09501936A JP 7507766 A JP7507766 A JP 7507766A JP 50776695 A JP50776695 A JP 50776695A JP H09501936 A JPH09501936 A JP H09501936A
Authority
JP
Japan
Prior art keywords
host
naked
following
method characterized
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP7507766A
Other languages
English (en)
Japanese (ja)
Inventor
デニス エイ． カーソン
イーヤル ラズ
メレディス エル． ハウエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JPH09501936A publication Critical patent/JPH09501936A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
JP7507766A 1993-08-26 1994-08-25 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置 Ceased JPH09501936A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11244093A 1993-08-26 1993-08-26
US08/112,440 1993-08-26
PCT/US1994/009661 WO1995005853A1 (en) 1993-08-26 1994-08-25 Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004168972A Division JP2004331668A (ja) 1993-08-26 2004-06-07 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための医薬、組成物およびシステム

Publications (1)

Publication Number Publication Date
JPH09501936A true JPH09501936A (ja) 1997-02-25

Family

ID=22343912

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7507766A Ceased JPH09501936A (ja) 1993-08-26 1994-08-25 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
JP2004168972A Pending JP2004331668A (ja) 1993-08-26 2004-06-07 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための医薬、組成物およびシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004168972A Pending JP2004331668A (ja) 1993-08-26 2004-06-07 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための医薬、組成物およびシステム

Country Status (6)

Country Link
EP (1) EP0714308A4 (de)
JP (2) JPH09501936A (de)
AU (1) AU705889B2 (de)
CA (1) CA2169635C (de)
MX (1) MX9406552A (de)
WO (1) WO1995005853A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515052A (ja) * 1997-08-13 2001-09-18 ザ ユーエイビー リサーチ ファンデーション 遺伝子ベクターの局所施用によるワクチン接種
JP2002512186A (ja) * 1998-04-20 2002-04-23 トレイ パインズ インスティチュート フォー モレキュラー スタディーズ ランゲルハンス細胞遊走を誘導する局所的免疫刺激
JP2002535100A (ja) * 1999-01-28 2002-10-22 サイト パルス サイエンシズ、インコーポレイテッド 細胞内への巨大分子の送達
JP2005526016A (ja) * 2002-01-25 2005-09-02 グラクソ　グループ　リミテッド Ｄｎａの投薬形態
JP2011103893A (ja) * 1999-03-16 2011-06-02 Sanofi Pasteur Ltd 組換えインフルエンザ菌アドヘシンタンパク質
JP2015515865A (ja) * 2012-05-10 2015-06-04 コリア ハイドロ アンド ニュークリア パワー カンパニー リミティッド 低レベル電離放射線に敏感な遺伝子の検出方法及び該方法により検出された遺伝子

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068863C (en) 1989-11-16 2009-06-02 Stephen A. Johnston Particle-mediated transformation of animal tissue cells
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998045408A2 (en) * 1996-04-10 1998-10-15 Heska Corporation Novel ectoparasite saliva proteins and apparatus to collect such proteins
US20020169104A1 (en) 1997-05-01 2002-11-14 Glenn Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
GB9505777D0 (en) * 1995-03-22 1995-05-10 Zeneca Ltd Process
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
GB9709900D0 (en) 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
JP2000500744A (ja) 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
AU724716B2 (en) * 1996-02-12 2000-09-28 Ml Laboratories Plc Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
TW480282B (en) * 1996-04-24 2002-03-21 Ren Wen Corp Recombinant eucaryotic vector containing allergen gene and use of preventing and treating allergic disease thereof
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
EP1872786A1 (de) 1997-09-05 2008-01-02 The Regents of the University of California Verwendung von immunstimulatorischen Oligonukleotiden zur Vorbeugung und Verringerung von antigen-stimulierten, granulozyten-vermittelten Entzündungen
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
WO1999036563A1 (en) * 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression
JP2002502831A (ja) * 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999058098A2 (en) 1998-05-12 1999-11-18 Bock Susan C HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2410371C (en) 2000-06-22 2015-11-17 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60124313T2 (de) 2001-01-15 2007-05-31 Keryos S.P.A. Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003101398A2 (en) 2002-05-31 2003-12-11 University Of Utah Research Foundation Variants of antithrombin iii
US6946186B2 (en) 2002-08-24 2005-09-20 International Paper Co. Uncoated facestock for adhesive-backed labels
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1721004A2 (de) 2004-02-24 2006-11-15 Innogenetics N.V. Verfahren zur bestimmung des risikos einer neurologischen krankheit
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
CA2595704A1 (en) * 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
DK3067066T3 (da) 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
SI3067066T1 (sl) 2007-02-23 2019-08-30 Prothena Biosciences Limited Preventiva in zdravljenje sinukleinopatske in amiloidogene bolezni
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5496897B2 (ja) 2007-10-04 2014-05-21 ザイモジェネティクス， インコーポレイテッド Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2231181B1 (de) 2007-12-17 2016-02-17 Marfl AB Neuer impfstoff zur behandlung von erkrankungen durch myobacterium
HUE025560T2 (en) 2007-12-28 2016-03-29 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2547654T3 (es) * 2008-10-31 2015-10-07 Tremrx, Inc. Vacunación con vectores poxvirales mediante alteración mecánica epidérmica
CA2802017A1 (en) 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
PT2758433T (pt) 2011-09-19 2018-01-19 Axon Neuroscience Se Terapia à base de proteínas e diagnóstico de patologia mediada por tau na doença de alzheimer
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
AU570998B2 (en) * 1983-09-07 1988-03-31 Takeda Chemical Industries Ltd. Topical steroid compositions for acne
ATE277193T1 (de) * 1989-03-21 2004-10-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5157020A (en) * 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
NZ239274A (en) * 1991-08-05 1995-12-21 Zenith Technology Corp Ltd Scratch fluid medicament applicator for applying a vaccine to an animal
IL108449A (en) * 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014101379A (ja) * 1997-08-13 2014-06-05 Uab Research Foundation 遺伝子ベクターの局所施用によるワクチン接種
JP2001515052A (ja) * 1997-08-13 2001-09-18 ザ ユーエイビー リサーチ ファンデーション 遺伝子ベクターの局所施用によるワクチン接種
JP2011068658A (ja) * 1997-08-13 2011-04-07 Uab Research Foundation 遺伝子ベクターの局所施用によるワクチン接種
JP2002512186A (ja) * 1998-04-20 2002-04-23 トレイ パインズ インスティチュート フォー モレキュラー スタディーズ ランゲルハンス細胞遊走を誘導する局所的免疫刺激
JP2002535100A (ja) * 1999-01-28 2002-10-22 サイト パルス サイエンシズ、インコーポレイテッド 細胞内への巨大分子の送達
JP2011103893A (ja) * 1999-03-16 2011-06-02 Sanofi Pasteur Ltd 組換えインフルエンザ菌アドヘシンタンパク質
JP2005526016A (ja) * 2002-01-25 2005-09-02 グラクソ　グループ　リミテッド Ｄｎａの投薬形態
JP2015515865A (ja) * 2012-05-10 2015-06-04 コリア ハイドロ アンド ニュークリア パワー カンパニー リミティッド 低レベル電離放射線に敏感な遺伝子の検出方法及び該方法により検出された遺伝子
US9512489B2 (en) 2012-05-10 2016-12-06 Korea Hydro & Nuclear Power Co., Ltd. Method for detecting genes sensitive to low-level ionizing radiation
US9708669B2 (en) 2012-05-10 2017-07-18 Korea Hydro & Nuclear Power Co., Ltd. Method for detecting genes sensitive to low-level ionizing radiation
US9708670B2 (en) 2012-05-10 2017-07-18 Korea Hydro & Nuclear Power Co., Ltd. Method for detecting genes sensitive to low-level ionizing radiation
US9708668B2 (en) 2012-05-10 2017-07-18 Korea Hydro & Nuclear Power Co., Ltd. Method for detecting genes sensitive to low-level ionizing radiation
US9714453B2 (en) 2012-05-10 2017-07-25 Korea Hydro & Nuclear Power Co., Ltd. Method for detecting genes sensitive to low-level ionizing radiation

Also Published As

Publication number Publication date
CA2169635A1 (en) 1995-03-02
EP0714308A4 (de) 1998-07-29
CA2169635C (en) 2002-11-12
MX9406552A (es) 1997-02-28
WO1995005853A1 (en) 1995-03-02
AU705889B2 (en) 1999-06-03
JP2004331668A (ja) 2004-11-25
AU7639194A (en) 1995-03-21
EP0714308A1 (de) 1996-06-05

Similar Documents

Publication Publication Date Title
JPH09501936A (ja) 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
US5985847A (en) Devices for administration of naked polynucleotides which encode biologically active peptides
US5830877A (en) Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
DE69534946T2 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
CA2204253C (en) Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides
WO1995005853A9 (en) Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
EP0935470B1 (de) Verfahren zur behandlung von allergischen lungenkrankheiten
JP4359654B2 (ja) 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
JP2001516729A (ja) 皮膚の抗原提示細胞に遺伝子を運搬する方法
JPH08508252A (ja) 小胞体シグナル配列ペプチドと少なくとも１個の他のペプチドをエンコードする核酸配列を含有する免疫原性キメラ、及びこのキメラのワクチン及び疾患の治療における使用
KR102156324B1 (ko) 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물
DE69815144T2 (de) Verfahren zur in vivo dns-verabreichung durch verwendung eines nadelfreien geräts
KR20210088446A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 황반변성의 예방 또는 치료용 조성물
WO2025002352A1 (zh) 一种含有阳离子脂质的药物组合物及其用途
KR20070027944A (ko) Ｆｉｚｚ를 포함하는 천식 예방 또는 치료 조성물
KR20020038578A (ko) 비-침입성 유전자 면역, 이로부터의 발현 산물, 및 이의용도
WO2001047530A1 (en) A method of therapy and prophylaxis of inflammation

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040705

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040805

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040805

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050117

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050413

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20050613